Author

A. Acker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. Do· 1 shared A. N. Hata· 1 shared A. Shiba-Ishii· 1 shared B. Y. Yeap· 1 shared I. Dagogo-Jack· 1 shared J. F. Gainor· 1 shared J. J. Lin· 1 shared J. L. Barth· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Do

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

A. Shiba-Ishii, T. W. Johnson, I. Dagogo-Jack, M. Mino-Kenudson, T. R. Johnson, P. Wei, S. L. Weinrich, M. A. McTigue, M. A. Walcott, L. Nguyen-Phuong, K. Dionne, A. Acker, L. Kiedrowski, A. Do, J. L. Peterson, , A. N. Hata

This study identifies lorlatinib-resistant ALK mutations and evaluates analogs to develop targeted therapies for compound resistance in ALK-positive lung cancer.

Nature Cancer · Jun 20, 2022Peer-reviewedCancer Biology